Work

Long-term safety and tolerability of frespaciguat: the INSIGNIA-PAH extension

Year: 2025

Type: article

Abstract: Extract Pulmonary arterial hypertension (PAH) is a progressive, life-threatening disease requiring long-term management to prevent right ventricular failure and improve outcomes [1, 2]. Despite advancements in PAH vasodilator therapies targeting the endothelin, prostacyclin, and nitric oxide pathways, systemic side effects remain a challenge that often limit optimal dosing, particularly with use of combination regimens [3]. While inhaled options exist, frequent administration and systemic side effects pose challenges [4, 5].

Source: European Respiratory Journal

DOI: 10.1183/13993003.01459-2025

Authors: Marc Humbert, Paul M. Hassoun, Kelly M. Chin, Guillermo Bortman, Humberto Garcia-Aguilar, Carmen La Rosa, Mackenzie Ford, Wei Fu, PoYao Niu, Maria José Loureiro, Marius M. Hoeper

Institutions: Inserm, Université Paris-Saclay, Assistance Publique – Hôpitaux de Paris, Bicêtre Hospital, Johns Hopkins University, The University of Texas Southwestern Medical Center, Merck & Co., Inc., Rahway, NJ, USA (United States), Medizinische Hochschule Hannover

Language: English

Topic: Pulmonary Hypertension Research and Treatments

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: hybrid

OpenAlex ID: W4416176224

FWCI: 1.181

Cites: 10

Cited by: 2

Related to: